Objective To explore the cognitive function and the level of serum homocysteine(Hcy) in patients with depression after cerebral infarction,and to analyze their correlation. Methods Fifty-two pa-tients with cerebral infarction and 50 patients with depression after cerebral infarction were selected.The cog-nitive function of patients was evaluated by Montreal cognitive assessment( MoCA) score and event-related potentials P300.Hcy concentration was detected by enzyme-linked immunosorbent assay(ELISA),and the correlation between the cognitive function and the Hcy concentration was analyzed. Results Compared with the patients without depression after cerebral infarction(MoCA(25.02±6.12),latency of P300(317.00± 28.87)ms,amplitued of P300(7.80±3.10)μV),the MoCA score of the patients with depression after cere-bral infarction significantly decreased(20.92±6.23),the latency of P300((370.84±40.62)s) significantly prolonged and the amplitude of P300((5.70±2.13)μV) significantly decreased(all P＜0.05).Compared with patients without depression after cerebral infarction(9/52,17.3%),the percent of serum hyper-Hcy in the patients with depression after cerebral infarction(24/50,48.0%) increased,and the difference was statisti- cally significant (χ2＝10.972,P＜0.01).The level of Hcy in the patients with depression after cerebral infarc-tion was negatively correlated with the score of MoCA ( r＝－0.675,P＜0.05) and the latency of P300 ( r＝0.813,P＜0.05),but negatively correlated with the amplitude of P300 (r＝－0.725,P＜0.05). Conclusion -Patients with depression after cerebral infarction have different degrees of cognitive impairment,and increased Hcy may be one of the factors that cause cognitive impairment in patients with depression after cerebral in-farction.

In order to verify whether p-nitrophenylalanine-containing BAFF vaccine can be used as a candidate molecule for the treatment of autoimmune diseases with BAFF over-expression,a soluble mutant of B cell activating factor belonging to the TNF Family (smBAFF) and its pNO2Phe mutant(pNO2Phe65smBAFF),which site specific incorporated pNO2Phe at position 65 of smBAFF,were expressed and purified.In order to evaluate the feasibility of using pNO2Phe65 smBAFF to treat BAFF-over-expressed autoimmune diseases,we investigate its Lymphocyte-stimulating capacity,immunogenicity and inhibitory effect of serum on biological activity of natural BAFF.The pharmacological activity of pNO2Phe65 smBAFF was evaluated using a cGVHD(graft-versus-host disease) induced SLE mouse model.Results indicated that pNO2Phe65 smBAFF,could bind to mouse lymphocytes but could not promote the proliferation of mouse lymphocytes.Moreover,the incorporation of pNO2Phe significantly increased the immunogenicity and induced cross-antibody,which can inhibit the biological activity of natural BAFF.In cGVHD induced SLE mouse model,pNO2Phe65 smBAFF can significantly reduce the symptoms of the disease and play a therapeutic role.Therefore,pNO2Phe65 smBAFF can be used as a candidate molecule for the treatment of autoimmune diseases with BAFF over-expression.

Objective To observe the effects of ziprasidone and risperidone on schizophrenia patients and the change of serum leptin and adiponectin levels .Methods Totally 80 cases of schizophrenia patients were randomly divided into ziprasidone group and risperidone group ,which were treated for 8 weeks .Measure the positive and negative symptoms scale (PANSS) score and body weight of that number ,leptin and adiponectin at baseline ,treatment 4 weeks and 8 weeks respectively for patients ,at the end of the experiment ,the results for statistical analysis .Results Two groups of 4 ,8 weeks after treatment scores compared with baseline scores dropped significantly ,the difference was statistically significant(P<0 .05) .Risperidone group after treatment ,leptin levels significantly increased body mass index ,and adiponectin levels significantly decreased ,compared with the baseline before treatment was statistically significant difference(P<0 .05) .Conclusion Ziprasidone and risperidone in treatment of schizophrenia have similar efficacy .Ziprasidone has no significant effect on body weight ,leptin and adiponectin levels in treatment of schizophrenia patients . However ,risperidone has a significant effect ,long-term use should pay attention to the side effects .

Objective To observe the effects of ziprasidone and risperidone on patients with schizophrenia and their influence on bloodglucoseandlipids.Methods 96patientswithschizophrenicenrolledinthestudywererandomlydividedintotwogroups,zi‐prasidone and risperidone group ,and both were treated for 8 weeks .Their blood glucose ,blood lipid of base line and at the end of the 4th ,8th week were determined respectively .Results The positive and negative symptoms scores of the two groups by using Positive and Negative Syndrome Scale(PANSS) before and after treatment were not statistically different(P> 0 .05) .Compared with the baseline scores ,scores at the end of 4th and 8th week in both ziprasidone and risperidone groups significantly decreased(P<0 .05) ,but there was no statistically significant difference between the two groups(P>0 .05) .After 8 weeks′ treatment ,the ef‐fective rate was 91 .7% in ziprasidone groups and 89 .6% in risperidone group .There were no significant differences between the two groups(P>0 .05) .The blood lipids and glucose levels were less increased after ziprasidone treatment ,but was not statistically significant(P>0 .05) .The blood lipids and glucose levels significantly increased after risperidone treatment(P<0 .05) .Conclusion Ziprasidone and risperidone had the same effect on schizophrenia .Ziprasidone had no effect on blood glucose and lipids in schizo‐phrenic patients ,while risperidone could increase blood glucose and lipids level ,we should pay attention to the side effects of long‐term use .